1. Home
  2. TBBK vs NVAX Comparison

TBBK vs NVAX Comparison

Compare TBBK & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBBK
  • NVAX
  • Stock Information
  • Founded
  • TBBK 1999
  • NVAX 1987
  • Country
  • TBBK United States
  • NVAX United States
  • Employees
  • TBBK N/A
  • NVAX N/A
  • Industry
  • TBBK Major Banks
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TBBK Finance
  • NVAX Health Care
  • Exchange
  • TBBK Nasdaq
  • NVAX Nasdaq
  • Market Cap
  • TBBK 2.4B
  • NVAX 1.3B
  • IPO Year
  • TBBK 2004
  • NVAX 1995
  • Fundamental
  • Price
  • TBBK $62.10
  • NVAX $7.12
  • Analyst Decision
  • TBBK Buy
  • NVAX Buy
  • Analyst Count
  • TBBK 3
  • NVAX 5
  • Target Price
  • TBBK $65.33
  • NVAX $16.60
  • AVG Volume (30 Days)
  • TBBK 553.7K
  • NVAX 5.1M
  • Earning Date
  • TBBK 07-24-2025
  • NVAX 08-07-2025
  • Dividend Yield
  • TBBK N/A
  • NVAX N/A
  • EPS Growth
  • TBBK 20.50
  • NVAX N/A
  • EPS
  • TBBK 4.42
  • NVAX 2.97
  • Revenue
  • TBBK $502,282,000.00
  • NVAX $1,254,962,000.00
  • Revenue This Year
  • TBBK N/A
  • NVAX $56.85
  • Revenue Next Year
  • TBBK $6.71
  • NVAX N/A
  • P/E Ratio
  • TBBK $14.14
  • NVAX $2.37
  • Revenue Growth
  • TBBK 10.02
  • NVAX 25.92
  • 52 Week Low
  • TBBK $38.21
  • NVAX $5.01
  • 52 Week High
  • TBBK $65.84
  • NVAX $17.81
  • Technical
  • Relative Strength Index (RSI)
  • TBBK 76.18
  • NVAX 57.25
  • Support Level
  • TBBK $55.58
  • NVAX $6.54
  • Resistance Level
  • TBBK $63.70
  • NVAX $6.90
  • Average True Range (ATR)
  • TBBK 1.80
  • NVAX 0.29
  • MACD
  • TBBK 0.78
  • NVAX 0.06
  • Stochastic Oscillator
  • TBBK 88.60
  • NVAX 92.52

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: